Clinicopathological characteristics of myelodysplastic syndromes with del(5q) in Taiwan

被引:0
|
作者
Yang, Ching -Fen [1 ,2 ]
Hsu, Chih-Yi [1 ,2 ,3 ]
Hsiao, Liang-Tsai [2 ,4 ,5 ]
Chen, Shang -Wen [6 ]
Chuang, Shih-Sung [7 ,8 ]
机构
[1] Taipei Vet Gen Hosp, Dept Pathol & Lab Med, Taipei, Taiwan
[2] Natl Yang Ming Chiao Tung Univ, Sch Med, Taipei, Taiwan
[3] Natl Taipei Univ Nursing & Hlth Sci, Coll Nursing, Taipei, Taiwan
[4] Taipei Vet Gen Hosp, Dept Med, Div Haematol, Taipei, Taiwan
[5] Taipei Vet Gen Hosp, Haemophilia Comprehens Care Ctr, Taipei, Taiwan
[6] Chi Mei Hosp, Dept Internal Med, Div Hematooncol, Lioying, Tainan, Taiwan
[7] Chi Mei Med Ctr, Dept Pathol, Tainan, Taiwan
[8] Chi Mei Med Ctr, Dept Pathol, 901 Chung Hwa Rd, Tainan 71004, Taiwan
关键词
5q deletion syndrome; chromosome aberrations; myelodysplastic syndrome; prognosis; progression -free survival; PROGNOSTIC SCORING SYSTEM; CYTOGENETIC ABNORMALITIES; DELETION; 5Q; FEATURES; MDS; CHROMOSOME-5; KARYOTYPE; SURVIVAL; SINGLE;
D O I
暂无
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Background: Myelodysplastic syndromes (MDS) are a group of clonal haematopoietic stem cell disorders characterised by ineffective haematopoiesis and cytopenia. Studies have reported differences in MDS between Asian and Western countries, but data from Taiwan are scarce. Materials and Methods: In this study we analysed the clinical and pathological features of 32 Taiwanese MDS patients with del(5q) (ie, del(5q) alone [Group A, n = 11], del(5q) with one additional cytogenetic abnormality other than monosomy 7 or del(7q) [Group B, del(5q)+1; n = 6], and del(5q) with >= 2 and overall survival (OS) were more favourable for Group A than for Groups B (p < 0.05) and C (p <= 0.001). Multivariate analysis showed that age >70 years, thrombocytopenia, and karyotype other than del(5q) alone were poor prognostic factors. Among the patients that had World Health Organization (WHO)-defined MDS with isolated del(5q), one patient (9%) had a typical marrow morphology of 5q minus syndrome with erythroid hypoplasia and four patients (36%) had hypolobated megakaryocytes. In addition, PFS and OS were significantly more favorable for the patients with del(5q) alone than for those with del(5q)+1 (p < 0.05). Conclusion: The bone marrow morphology, clinical features, and prognosis of Taiwanese MDS patients with del(5q) were different from those associated with MDS with isolated del(5q) as defined in the current WHO classification. Researchers should compare different geographic regions and racial populations to determine whether geographic and racial differences exist with respect to MDS with del(5q).
引用
收藏
页码:405 / 416
页数:12
相关论文
共 50 条
  • [1] Lenalidomide for del(5q) and Non-del(5q) Myelodysplastic Syndromes
    Giagounidis, Aristoteles A. N.
    SEMINARS IN HEMATOLOGY, 2012, 49 (04) : 312 - 322
  • [2] Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond
    Talati, Chetasi
    Sallman, David
    List, Alan
    SEMINARS IN HEMATOLOGY, 2017, 54 (03) : 159 - 166
  • [3] Cytogenetics of myelodysplastic syndromes and detection of del 5q
    Mufti, G.
    LEUKEMIA RESEARCH, 2007, 31 : S8 - S9
  • [4] Higher-risk myelodysplastic syndromes with del(5q): does the del(5q) matter?
    Gorshein, Elan
    Weber, Urs M.
    Gore, Steven
    EXPERT REVIEW OF HEMATOLOGY, 2020, 13 (03) : 233 - 239
  • [5] Blood consult: treating del(5q) myelodysplastic syndromes
    Mukherjee, Sudipto
    Tiu, Ramon V.
    Sekeres, Mikkael A.
    BLOOD, 2012, 119 (02) : 342 - 344
  • [6] Variability in the extent of del(5q) in myelodysplastic syndromes (MDS)
    Zemanova, Zuzana
    Brezinova, Jana
    Svobodova, Karla
    Lhotska, Halka
    Vesela, Denisa
    Belickova, Monika
    Vesela, Jitka
    Izakova, Silvia
    Sarova, Iveta
    Lizcova, Libuse
    Ransdorfova, Sarka
    Pavlistova, Lenka
    Cermak, Jaroslav
    Stopka, Tomas
    Jonasova, Anna
    Michalova, Kyra
    MOLECULAR CYTOGENETICS, 2019, 12
  • [7] MOLECULAR MECHANISMS OF LENALIDOMIDE RESISTANCE IN DEL(5Q) MYELODYSPLASTIC SYNDROMES
    Martinez-Hoyer, Sergio
    Deng, Yu
    Parker, Jeremy
    Jiang, Jihong
    Docking, Roderick
    Mo, Angela
    Gharaee, Nadia
    Jadersten, Martin
    Kulasekararaj, Austin
    Malcovati, Luca
    List, Alan
    Hellstrom-Lindberg, Eva
    Platzbecker, Uwe
    Karsan, Aly
    EXPERIMENTAL HEMATOLOGY, 2020, 88 : S72 - S72
  • [8] Myelodysplastic syndromes with del(5q): indications and strategies for cytogenetic testing
    Haferlach, Claudia
    Bacher, Ulrike
    Tiu, Ramon
    Maciejewski, Jaroslaw P.
    List, Alan
    CANCER GENETICS AND CYTOGENETICS, 2008, 187 (02) : 101 - 111
  • [9] Myelodysplastic syndromes del(5q): Pathogenesis and its therapeutic implications
    Bruzzese, Antonella
    Martino, Enrica Antonia
    Mendicino, Francesco
    Lucia, Eugenio
    Olivito, Virginia
    Capodanno, Isabella
    Neri, Antonino
    Morabito, Fortunato
    Vigna, Ernesto
    Gentile, Massimo
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2024, 112 (06) : 860 - 869
  • [10] Conditional Survival in Patients with Del(5q) Myelodysplastic Syndromes Treated with Lenalidomide
    Gerds, Aaron T.
    List, Alan F.
    Giagounidis, Aristoteles
    Hellstrom-Lindberg, Eva
    Li, Jack Shiansong
    Swern, Arlene S.
    Sugrue, Mary M.
    Fenaux, Pierre
    Sekeres, Mikkael A.
    BLOOD, 2015, 126 (23)